New antibody therapy targets Hard-to-Treat prostate cancer

NCT ID NCT07529717

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 4 times

Summary

This study tests an experimental drug called AZD8359 for men with metastatic prostate cancer that has spread and is no longer responding to standard treatments. The drug is designed to guide the body's immune cells to attack cancer cells. The trial will first find the safest dose and then test it in a larger group to see if it can shrink tumors or lower PSA levels.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PROSTATE CANCER

Contacts and locations

Locations

Research Site
RECRUITING

Orlando, Florida, 32806, United States
Research Site
RECRUITING

East Brunswick, New Jersey, 08816, United States
Research Site
NOT_YET_RECRUITING

Hackensack, New Jersey, 07601, United States
Research Site
RECRUITING

Providence, Rhode Island, 02903, United States
Research Site
RECRUITING

Darlinghurst, 2010, Australia
Research Site
RECRUITING

Melbourne, 3000, Australia
Research Site
RECRUITING

Seoul, 03722, South Korea
Research Site
RECRUITING

Seoul, 06351, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.